Clinical trial
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic…
NCT00267956 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00267956 |
|---|---|
| Title | An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis |
| Official title | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | CNTO 1275 63 mg, Placebo |
| Enrollment | 146 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Dec 22, 2005 |
| Last update posted | Jun 5, 2013 |
| Countries | Canada, Denmark, Finland, Switzerland, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: